PTPRN

Across TCGA pan-cancer cohorts, PTPRN mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PTPRN data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PTPRN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PTPRN expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and LUAD are the cancer types where PTPRN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.981	0.718	.013	14	view →
GBM	DFS	Quartile	All	0.858	0.648	.014	4	view →
LUAD	OS	Median	All	0.207	0.819	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PTPRN–PDAC (OS)

Open the PDAC breakdown →